Amino Acids in the Blood After Eating Yoghurt and Milk Proteins

NCT07243730 | Recruiting

• 1 other identifier: 25REX0091083
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Participants will visit the study site twice in a fasting state. Participants asked to consume one of the two study products in a random order. Participants will consume one serving of the study product (T = 0 minutes). Study product intake should take place within 10 minutes (+/-5 minutes). Two blood samples will be taken at baseline and then at 14 timepoints after product intake. A follow up call will take place 7 (-3/+7) days after the final study visit.

Conditions

Bioavailability of Amino Acids

Keywords

Amino acids; Yogurt; Milk

Outcome Measures

Primary Outcomes (1)

• Incremental Area Under the Curve (iAUC ₀-₁₂₀) for Essential Amino Acids (EAA) in Blood After Ingestion of Product A or Product B

  2 hours

Secondary Outcomes (4)

• Incremental Area Under the Curve (iAUC ₀-₃₀₀) for Essential Amino Acids in Blood After Ingestion of Product A or Product B

  5 hours

• Incremental Area Under the Curve (iAUC ₀-₁₂₀) for Total Amino Acids in Blood After Ingestion of Product A or Product B

  2 hours

• Incremental Area Under the Curve (iAUC ₀-₃₀₀) for Total Amino Acids in Blood After Ingestion of Product A or Product B

  5 hours

• Maximum Concentration (Cmax) of Total Amino Acids and Essential Amino Acids in Blood After Ingestion of Product A or Product B

  5 hours

Study Arms (2)

Yogurt first, Milk second

ACTIVE COMPARATOR

All subjects will receive 2 study products on separate visits in a randomized order.

Other: Full fat yogurt (fermented); Other: Generic full fat pasteurized milk (non-fermented)

Milk first, Yogurt second

ACTIVE COMPARATOR

All subjects will receive 2 study products on separate visits in a randomized order.

Other: Full fat yogurt (fermented); Other: Generic full fat pasteurized milk (non-fermented)

Interventions

Full fat yogurt (fermented) OTHER

Test

Milk first, Yogurt second; Yogurt first, Milk second

Generic full fat pasteurized milk (non-fermented) OTHER

Control

Milk first, Yogurt second; Yogurt first, Milk second

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age ≥ 18 and ≤ 40 years at the time of (Informed Consent Form) ICF signature
• Body Mass Index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2
• Signed informed consent
• Willingness and ability to comply with the protocol
• Judged by the Investigator to be in good health.

You may not qualify if:

• Any known surgery or ongoing medical condition that interferes significantly with protein absorption and digestion, and/or gastrointestinal (GI) function in the opinion of the investigator, including but not limited to the following: phenylketonuria, pancreatitis, short bowel syndrome, inflammatory bowel disease, celiac disease, gastroesophageal reflux disease, gastric ulcer, chronic gastritis, gastrointestinal cancer, esophageal and/or gastric surgery, and any cardiovascular disease (such as hypertension, arrhythmia, or atrial fibrillation) which is not controlled with the use of medication/therapy.
• Known renal or hepatic diseases that may interfere with protein metabolism in the opinion of the investigator, including but not limited to acute hepatitis, chronic liver disease, nephritis, cystinuria, chronic kidney disease.
• Use of systemic medication within the past 3 weeks prior to screening which in the opinion of the investigator may influence gastric acid production and/or gastrointestinal motility or function and/or protein metabolism (e.g., antibiotics, anticonvulsants, prokinetics, antacids or gastric acid inhibitors, opioid analgesics, anticoagulants, corticosteroids, laxatives, growth hormone, testosterone, immunosuppressants, or insulin).
• Known Diabetes Mellitus Type I or Type II, insulin resistance, or metabolic syndrome.
• Any ongoing cancer and/or cancer treatment (except for non-melanoma skin cancer or carcinoma in situ).
• Known anaemia.
• A blood donation within 56 days (8 weeks) for men; or 122 days (4 months) for women; prior to the screening.
• Any known bleeding disorder.
• Adherence to a strict dietary regime (e.g. vegetarian/ vegan/ paleo/ ketogenic/ intermittent fasting/ high protein diet (\>1.6 g/kg body weight/day)) or a weight loss program.
• Any known allergies or intolerances to ingredients of the study product, i.e. cow's milk allergies, lactose intolerance.
• Known pregnancy and/or lactation.
• Current smoking / vaping / use of e-cigarette / or stopped smoking for \< 1 month prior to screening (except for incidental smoking of ≤ 3 cigarettes/ e-cigarettes/ cigars/ pipes per week on average in the last month prior to screening).
• Average alcohol use of \> 21 glasses per week for men or \> 14 glasses per week for women (on average during the last 6 months prior to screening).
• Drug or medicine abuse in the opinion of the investigator.
• Current eating disorders, e.g. anorexia nervosa, bulimia nervosa, binge eating disorder.

Sponsors & Collaborators

• Nutricia Research: lead

Study Sites (1)

EB Medical Research

Almere Stad, Netherlands

RECRUITING

Central Study Contacts

Danone Global Research and Innovation Center

CONTACT

+31 30 2095 000; register.clinicalresearchnutricia@danone.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: A randomized controlled clinical study in healthy participants

Study Record Dates

• First Submitted: November 17, 2025
• First Posted: November 24, 2025
• Study Start: November 7, 2025
• Primary Completion: January 1, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: December 17, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

NL (1)